VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2014

Dec 5, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2014-12-04

Reporting Person: Connolly Thomas (SVP, Human Resources)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-12-04	Common Stock	M	937	$53.74	Acquired	35832	Direct
2014-12-04	Common Stock	S	500	$118.40	Disposed	35332	Direct
2014-12-04	Common Stock	S	337	$119.36	Disposed	34995	Direct
2014-12-04	Common Stock	S	100	$120.62	Disposed	34895	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-12-04	Stock Option (right to buy)	$53.74	M	937	Disposed	2022-09-03	Common Stock (937)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	150	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Connolly's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $118.40 (range $117.92 to $118.86).

F3: Mr. Connolly undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $119.36 (range $118.95 to $119.82).

F5: The option vests in 16 quarterly installments from 09/04/2012.